Company / Cash & Equivalents
IRADIMED CORP Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$51.2M
FY2025
5-year range
$49.8M / $62.0M
FY2021-FY2025
Trend
-2.1%
vs FY2024
Sector context
#129 of 148
Health Care
What the data says
IRADIMED CORP's cash & equivalents of $51M is lower than 87% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $9M in FY2016 to $62M in FY2021.
Based on SEC 10-K filings.
$51M in FY2025 with a 5-year CAGR of +0.4%.
Improved from $50M to $51M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -4.1%
- 5-Year CAGR
- +0.4%
- 10-Year CAGR
- -
Sector benchmark
Bottom 13% in Health CareTop 87% of 148This company $51.2M Sector average $1.2B
▼
-95.7% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.4%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 2.1% year-over-year.
- Ranks #129 out of 148 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.29 (safe zone, above 2.9 threshold)
- Strong profit margin: 24.1%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.2M | -2.1% |
| FY2024 | $52.2M | +5.0% |
| FY2023 | $49.8M | -14.1% |
| FY2022 | $58.0M | -6.5% |
| FY2021 | $62.0M | +23.8% |
| FY2020 | $50.1M | +15.1% |
| FY2019 | $43.5M | +55.1% |
| FY2018 | $28.0M | +53.9% |
| FY2017 | $18.2M | +92.6% |
| FY2016 | $9.5M | +284.1% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026